Abstract Background Antimicrobial resistance is an increasing cause of neonatal infection-related mortality. Colonization with carbapenem-resistant organisms (CRO) may precede and increase the risk for subsequent infection in neonates. In this study, we evaluated associations between CRO colonization and infectious outcomes among neonates admitted to a neonatal intensive care unit (NICU). Methods From July 2023 to February 2024, a prospective cohort study was conducted among neonates admitted to a tertiary hospital NICU. Neonates were assessed for CRO colonization using rectal swabs collected within 24 hours of admission, on days 3 and 7, and weekly until discharge, transfer, or death. Swabs were plated on selective agar followed by VITEK-2 identification and susceptibility testing. VITEK-2 was also used for blood and tracheal aspirate culture isolates in suspected sepsis cases. Risk ratios (RR) and other analyses were performed using Stata v15. Results From July 2023 to February 2024, 423 neonates were enrolled (median age 4 days; IQR 2–8), 62% male. At enrollment, 51% (214) were colonized with CROs. Of those who were not colonized at enrollment, 80% (167/209) acquired colonization during their hospital stay (Figure 1). Among CRO-colonized neonates, 71% had Klebsiella pneumoniae (Kpn), 36% Pseudomonas aeruginosa, 36% Acinetobacter baumannii, and 31% Escherichia coli (Figure 2). Clinically suspected infections occurred in 113 (27%) neonates. Of 33 positive bacterial cultures, 10 (30%) were CROs, including Kpn (4), E. meningoseptica (2), A. baumannii (1), A. lwoffii (1), E. coli (1), and B. cepacia (1). Three clinical isolates had antibiotic susceptibility patterns matching with colonized strains; all were CR-Kpn. CRO colonization at any time point was associated with confirmed bacterial infection (RR 1.11, 95% CI 1.05–1.17). Conclusion CRO colonization was common among NICU patients and increased throughout the hospital stay. These findings highlight the urgent need of targeted prevention strategies to reduce CRO transmission and infection risk among this vulnerable population. Disclosures All Authors: No reported disclosures
Chowdhury et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: